Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Osteoporosis International
Published in: Osteoporosis International 2/2007

01-02-2007 | Case Report

Integrated anti-remodeling and anabolic therapy for the osteoporosis of Hajdu–Cheney syndrome

Author: F. E. McKiernan

Published in: Osteoporosis International | Issue 2/2007

Login to get access

Abstract

Hajdu–Cheney syndrome (MIM 102500) is a rare skeletal dysplasia marked by severe generalized osteoporosis and focal bone loss (acro-osteolysis). Osteoporosis treatment outcome has been reported only once previously. Reported herein is the biochemical and densitometric response to integrated anti-remodeling and anabolic therapy in a woman with Hajdu–Cheney syndrome. Results suggest dissociation of bone formation from bone resorption resulting in dramatic increases in bone mineral density without clinical evidence of activated osteoporosis.
Literature
1.
Hajdu N, Kauntze R (1948) Cranio-skeletal dysplasia. Br J Radiol 21:42–48PubMed
2.
Cheney WD (1965) Acro-osteolysis, Am J Roentgenol 94:595
3.
Brennan AM, Pauli RM (2001) Hajdu–Cheney syndrome: evolution of phenotype and clinical problems. Am J Med Genet 100:292–310PubMedCrossRef
4.
Drake WM, Hiorns MP, Kendler DL (2003) Hajdu–Cheney syndrome: response to therapy with bisphosphonates in two patients. J Bone Miner Res 18:131–133PubMedCrossRef
5.
Hocking J, Conoyer S, McKiernan F (2006) Bone mineral density studies in two patients with Hajdu–Cheney syndrome. J Clin Densitom 9:230CrossRef
6.
Hermann J, Zubige F (1973) Arthro-dento-osteo-dysplasia (Hajdu–Cheney syndrome). Z Kinderheilkd 114:93–110CrossRef
7.
Weleber RG, Beals RK (1976) The Hajdu–Cheney syndrome. J Peds 88:243–249CrossRef
8.
Crifasi PA, Patterson MC, Bonde D, Michels VV (1997) Severe Hajdu–Cheney syndrome with upper airway obstruction. Am J Med Genet 70:261–266PubMedCrossRef
9.
10.
Brown DM, Gorkin RJ, Desnick RJ, Langer Jr LO, Jowsey J, Sauk Jr JJ (1976) The acro-osteolysis syndrome; morphologic and biochemical studies. J Pediatr 88:573–580CrossRef
11.
Iwaya T, Taniguchi K, Watanabe J, Iinuma K, Hamazaki Y (1979) Hajdu–Cheney syndrome. Arch Orthop Traumat Surg 95:293–302CrossRef
12.
Udell J, Schumacher Jr HR, Kaplan F, Fallon MD (1986) Idiopathic familial acroosteolysis: histomorphometric study of bone and literature review of the Hajdu–Cheney syndrome. Arth Rheum 29:1032–1038CrossRef
13.
Elias AN, Pinals RS, Anderson HC (1978) Hereditary osteodysplasia with acro-osteolysis. Am J Med 65:627–636PubMedCrossRef
14.
Blumenauer BT, Cranney AB, Goldstein R (2002) Acro-osteolysis and osteoporosis as manifestations of the Hajdu–Cheney syndrome. Clin Exp Rheumatol 20:474–475
15.
Leidig-Bruckner G, Pfeilschifter J, Penning N (1999) Severe osteoporosis in familial Hajdu–Cheney syndrome; progression of acro-osteolysis and osteoporosis during long-term follow-up. J Bone Miner Res 14:2036–2041PubMedCrossRef
16.
Nunziata V, Di Giovanni G, Baltanti P, Bonucci E (1990) High turnover osteoporosis in acro-osteolysis (Hajdu–Cheney syndrome). J Endocrinol Invest 3:251–255
17.
Bauer DC, Garnero P, Hochberg MC, Santora A, Delmas P, Ewing SK, Black DM (2006) Pretreatment levels of bone turnover and the antifracture efficacy of alendronate: the fracture intervention trial. J Bone Miner Res 21:292–299PubMedCrossRef
18.
Delmas PD, Licata AA, Reginster JY, Crans GG, Chen P, Misurski DA, Wagman RB, Mitlak BH (2006) Fracture risk reduction during treatment with teriparatide is independent of pretreatment bone turnover. Bone 39:237–243PubMedCrossRef
19.
Cosman F, Nieves J, Zion M, Woelfert L, Luckey M, Lindsay R (2005) Daily and cyclic parathyroid hormone in women receiving alendronate. N Engl J Med 353:566–575PubMedCrossRef
20.
Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH (2001) Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:1434–1441CrossRef
Metadata
Title
Integrated anti-remodeling and anabolic therapy for the osteoporosis of Hajdu–Cheney syndrome
Author
F. E. McKiernan
Publication date
01-02-2007
Publisher
Springer-Verlag
Published in
Osteoporosis International / Issue 2/2007
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI
https://doi.org/10.1007/s00198-006-0221-z

Other articles of this Issue 2/2007

Osteoporosis International 2/2007 Go to the issue

Original Article

Adherence of academic geriatric practitioners to osteoporosis screening guidelines

Original Article

Potential for bone turnover markers to cost-effectively identify and select post-menopausal osteopenic women at high risk of fracture for bisphosphonate therapy

Original Article

Incidence and costs of hip fractures compared to acute myocardial infarction in the Italian population: a 4-year survey

Original Article

COL1A1, ESR1, VDR and TGFB1 polymorphisms and haplotypes in relation to BMD in Spanish postmenopausal women

Review

Anti-epileptic medication and bone health

Original Article

Menstrual cycle lengths and bone mineral density: a cross-sectional, population-based study in rural Chinese women ages 30–49 years